Screening and Engineering of Hetero-Bivalent Nanobody Targeting Interleukin-33 with Enhanced Binding Stability
Biomolecules · 23.06.2026 · 16 (7) · 936
DOI: 10.3390/biom16070936 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 23.06.2026. Verfasst von Yingxin Zhou und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Wannan Medical University, Wuhu 241002, China. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Interleukin-33, Protein Engineering. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wannan Medical College, Wannan Medical University.
Abstract (Originalsprache)
Interleukin-33 (IL-33) is an IL-1 family cytokine that functions as an alarmin and contributes to inflammatory responses, immune regulation, and tumor-associated processes through the IL-33/ST2 signaling axis. In this study, IL-33-specific nanobodies were isolated from a synthetic phage display library and further engineered into bivalent tandem formats to improve their binding performance. Five representative monovalent nanobodies showed concentration-dependent binding to IL-33, with SPR-derived KD values ranging from 3.6 × 10−8 to 2.81 × 10−7 M. Among the engineered bivalent constructs, Nb1–Nb2 exhibited the strongest apparent binding affinity, mainly due to a markedly reduced dissociation rate. Competitive SPR analysis indicated that Nb1 and Nb2 show largely compatible binding to IL-33, consistent with distinct or minimally overlapping binding regions, supporting their selection as a hetero-bivalent pair. In a preliminary wound-healing assay using HT-29 colorectal cancer cells, Nb1–Nb2 attenuated IL-33-induced wound closure under low-serum conditions. These results indicate that hetero-bivalent engineering can enhance the apparent binding affinity of IL-33-targeting nanobodies and provide a useful molecular tool for further investigation of IL-33-associated biological responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medical Sciences, Wannan Medical University, Wuhu 241002, China.
- Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.
ORCID-Profile: Yingxin Zhou
Förderung
- Wannan Medical College
- Wannan Medical University
Zitieren
APA
Zhou, Y., Shi, L., & Wang, W. (2026). Screening and Engineering of Hetero-Bivalent Nanobody Targeting Interleukin-33 with Enhanced Binding Stability. Biomolecules, 16(7), 936. https://doi.org/10.3390/biom16070936
Vancouver
Zhou Y, Shi L, Wang W. Screening and Engineering of Hetero-Bivalent Nanobody Targeting Interleukin-33 with Enhanced Binding Stability. Biomolecules. 2026;16(7):936. doi:10.3390/biom16070936
BibTeX
@article{Zhou2026,
author = {Zhou, Yingxin and Shi, Leilei and Wang, Weichen},
title = {Screening and Engineering of Hetero-Bivalent Nanobody Targeting Interleukin-33 with Enhanced Binding Stability},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {7},
pages = {936},
doi = {10.3390/biom16070936}
}
EUVIMED